New study showing variants of VEGF-A may influence visual acuity outcomes of anti-VEGF treatments.

A research team from the University of Melbourne, Australia has published data demonstrating a potential pharmacogenetic relationship between anti-VEGF treatments and visual acuity outcomes in individuals with VEGF-A gene variants. The study showed a statistically significant association between a particular VEGF-A SNP (single nucleotide polymorphism) and visual acuity outcome 6 months after treatment. From the data collected the authors of the study conclude that treatment may be more cost effective in certain groups of neovascular AMD patients. Further validation in a wider cohort of patients may allow clinicians to design more individualized treatment regimens based on genotype variants.